X0304 4 2012-03-12 0 0001100962 ENDO PHARMACEUTICALS HOLDINGS INC ENDP 0001297399 Spengler William C/O ENDO PHARMACEUTICALS 100 ENDO BOULEVARD CHADDS FORD PA 19317 1 0 0 0 2010 Stock Incentive Plan Restricted Stock Options (RSU) 2012-03-12 4 A 0 5481 A 5481 D Common Stock, par value, $.01 per share 2012-03-12 4 M 0 1417 0.00 A 27539 D 2007 Stock Incentive Plan Restricted Stock Units (RSU) 2012-03-12 4 A 0 1417 0.00 D 2012-03-12 2012-03-12 Common Stock 1417 0 D Upon each vesting date, each vested restricted stock unit automatically converts into one (1) share of common stock of Endo Pharmaceuticals Holdings Inc. unless the director has elected to defer receipt of the vested shares under the Endo Pharmaceuticals Directors Deferred Compensation Plan. These restricted stock units (RSUs) generally vest 100% on March 12, 2013. Upon vesting, we consider the underlying RSUs to be expired. Pursuant to the Endo Pharmaceuticals Directors Deferred Compensation Plan, on December 13, 2011, Mr. Spengler elected to defer receipt of these RSUs. These securities were granted to Mr. Spengler in consideration of his services on the Endo Pharmaceutical Holdings Inc. Board of Directors. This represents vesting of restricted stock units granted to Mr. Spengler on March 12, 2010. Upon each vesting date, each vested restricted stock unit automatically converts into one (1) share of common stock of Endo Pharmaceuticals Holdings Inc. On December 15, 2009, Mr. Spengler elected to defer receipt of these shares pursuant to the Endo Pharmaceuticals Directors Deferred Compensation Plan. This number represents (i) 5,481 restricted stock units and (ii) 22,058 shares of common stock, receipt of which 19,940 has been deferred under the Endo Pharmaceuticals Directors Deferred Compensation Plan. Mr. Spengler's beneficial ownership disclosed in this table excludes all shares held by Mr. Spengler indirectly, including shares underlying stock options. Fifty percent (50%) of Mr. Spengler's March 12, 2010 grant of restricted stock units (RSUs) generally vest on each of March 12, 2011 and March 12, 2012. Upon vesting, we consider the underlying RSUs to be expired. The 1,417 shown here is the amount that vested on March 12, 2012. However, on December 15, 2009, Mr. Spengler elected to defer receipt of these shares pursuant to the Endo Pharmaceuticals Directors Deferred Compensation Plan. /s/ Caroline B. Manogue, by Power of Attorney 2012-03-14